CG OncologyCGON -1.22%12 Days Payable is 214.88 as of Mar. 2026, which is 55% below its 10-year median of 480.34. GuruFocus rates CGON with a GF Score™ of 12/100. The stock has 6 warning signs investors should review. Among 706 Biotechnology companies, CG Oncology ranks better than 73.51% on this metric.
The historical rank and industry rank for CG Oncology's Days Payable or its related term are showing as below:
CGON'
s Days Payable Range Over the Past 10 Years
Min: 354.96 Med: 480.34 Max: 480.34
Current: 354.96
During the past 5 years, CG Oncology's highest Days Payable was 480.34. The lowest was 354.96. And the median was 480.34.
CGON's Days Payable is ranked better than 73.51% of 706
companies
in the Biotechnology industry
Industry Median: 113.56
vs CGON: 354.96
CG Oncology's Days Payable
increased
from Mar. 2025 (0.00) to Mar. 2026 (214.88).
It may suggest that CG Oncologydelayed paying its suppliers.
CG Oncology Days Payable Related Terms
CG Oncology Days Payable Historical Data
* Premium members only.
The historical data trend for CG Oncology's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CG Oncology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CG Oncology Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CG Oncology's Days Payable distribution charts can be found below:
* The bar in red indicates where CG Oncology's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
CG Oncology's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CG Oncology (CGON) has a Days Payable of 214.88 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on CG Oncology and its competitors. This is 55% below median its historical median of 480.34. Over the past decade, CG Oncology's Days Payable has ranged from 354.96 to 480.34. According to the industry distribution chart, CG Oncology ranks #187 out of 706 companies in the Biotechnology industry, placing it in the top 26.5%.
Is CG Oncology's Days Payable too high?
CG Oncology's current Days Payable of 214.88 is 55% below median its 10-year median of 480.34. Over the past 10 years, this metric has ranged from a low of 354.96 to a high of 480.34. The Biotechnology industry median Days Payable is 113.56. CG Oncology's value of 214.88 is 89.2% above this industry median. Based on the distribution chart, CG Oncology ranks #187 out of 706 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CG Oncology has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does CG Oncology's Days Payable compare to CRSP and XENE?
According to the Biotechnology industry distribution chart, CG Oncology ranks #187 out of 706 companies for Days Payable. This puts CG Oncology in the upper half of its industry. The industry median Days Payable is 113.56. CG Oncology's value of 214.88 is 89.2% above this benchmark. Historically, CG Oncology's own Days Payable has ranged from 354.96 to 480.34 over the past decade. While the company's 10-year median is 480.34 vs. the industry median of 113.56, CG Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CG Oncology's current Days Payable of 214.88 is 89.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on CG Oncology and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CG Oncology's current Days Payable is 214.88, which is 55% below median its own 10-year median of 480.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CG Oncology stock overvalued right now?
CG Oncology (CGON) has a current Days Payable of 214.88. The current Days Payable is 214.88, which is 55% below median its 10-year median of 480.34 and 89.2% above the Biotechnology industry median of 113.56. CG Oncology's overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For CG Oncology (CGON), the current Days Payable is 214.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
12GF Score
Get the complete analysis for CGON
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGON has been successfully added to your 
